Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

Author(s): Asif Khurshid Qazi, Aashiq Hussain, Abid Hamid, Yasrib Qurishi, Rabiya Majeed, Mudassier Ahmad, Rauf Ahmad Najar, Javeed Ahmad Bhat, Shashank Kumar Singh, Mohmmad Afzal Zargar, Shakir Ali, Ajit Kumar Saxena

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 13 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.

Keywords: Anticancer target, cancer, inhibitors, PI3K-Akt-mTOR, Signaling, therapy, translation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 13 May, 2013
Page: [1552 - 1564]
Pages: 13
DOI: 10.2174/1871520613666131125123241
Price: $65

Article Metrics

PDF: 44